Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 18, 2023

Carboplatin and Paclitaxel Plus Avelumab for Advanced or Recurrent Endometrial Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
Lancet Oncol 2023 Feb 14;[EPub Ahead of Print], S Pignata, G Scambia, C Schettino, L Arenare, C Pisano, D Lombardi, U De Giorgi, C Andreetta, S Cinieri, C De Angelis, D Priolo, C Casanova, M Rosati, F Greco, E Zafarana, I Schiavetto, S Mammoliti, SC Cecere, V Salutari, S Scalone, A Farolfi, M Di Napoli, D Lorusso, P Gargiulo, D Califano, D Russo, A Spina, R De Cecio, P Chiodini, F Perrone

Further Reading